Undisclosed Pipeline Programs

About AS2 Bio

AS2 Bio is a private, pre-clinical stage biotech dedicated to creating therapies for Angelman syndrome (AS), a rare neurodevelopmental disorder. The company is building a pipeline across multiple therapeutic modalities, including targeted protein degradation, and is led by a team with deep experience in rare disease drug development and direct personal connections to the AS community. Its strategy is closely tied to the Foundation for Angelman Syndrome Therapeutics (FAST), leveraging established research consortia and regulatory pathways to advance its programs.

Therapeutic Areas

Other Angelman syndrome Drugs